Biden proposes massive expansion of US weight-loss drug coverage

Contributing sentiments towards policy:

56% : The number of additional potentially eligible patients under Medicare, which provides coverage for over-65s, is 3.4mn.
54% : A further 4mn Americans could be eligible under Medicaid, which applies to people with limited income and resources.
49% : The last-gasp move comes after the White House ushered in price negotiations for the most costly drugs covered by Medicare and a $35-a-month cap on out-of-pocket costs for diabetic patients using insulin.
49% : Mehmet Oz, the TV doctor who Trump nominated to run the Centers for Medicare and Medicaid Services, has previously praised Novo Nordisk's GLP-1 drug Ozempic.
46% : Medicaid covers weight-loss drugs for obesity alone in 14 states, including California, Michigan and Virginia, according to the AXIACI Obesity Coverage Nexus.
43% : Novo Nordisk and Eli Lilly, the leading weight-loss drugmakers, have been lobbying hard to expand Medicare and private insurance coverage of weight-loss drugs.
34% : It would need to be finalised after Trump takes office on January 20.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.